IL186374A - Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them - Google Patents

Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them

Info

Publication number
IL186374A
IL186374A IL186374A IL18637407A IL186374A IL 186374 A IL186374 A IL 186374A IL 186374 A IL186374 A IL 186374A IL 18637407 A IL18637407 A IL 18637407A IL 186374 A IL186374 A IL 186374A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
manufacture
treatment
combined use
proton pump
Prior art date
Application number
IL186374A
Other languages
English (en)
Hebrew (he)
Other versions
IL186374A0 (en
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of IL186374A0 publication Critical patent/IL186374A0/en
Publication of IL186374A publication Critical patent/IL186374A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL186374A 2005-04-12 2007-10-07 Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them IL186374A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67023805P 2005-04-12 2005-04-12
PCT/JP2006/308001 WO2006109881A1 (en) 2005-04-12 2006-04-11 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders

Publications (2)

Publication Number Publication Date
IL186374A0 IL186374A0 (en) 2008-03-20
IL186374A true IL186374A (en) 2013-05-30

Family

ID=36685683

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186374A IL186374A (en) 2005-04-12 2007-10-07 Combined use of prostaglandin compound and ppi for the manufacture of pharmacological compounds for the treatment of gastrointestinal disorders and pharmaceutical compounds containing them

Country Status (18)

Country Link
US (1) US8962688B2 (enExample)
EP (1) EP1871380B1 (enExample)
JP (2) JP5711442B2 (enExample)
KR (2) KR101466980B1 (enExample)
CN (1) CN101198334B (enExample)
AU (1) AU2006234632B2 (enExample)
BR (1) BRPI0610557A2 (enExample)
CA (1) CA2602812C (enExample)
DK (1) DK1871380T3 (enExample)
ES (1) ES2371658T3 (enExample)
IL (1) IL186374A (enExample)
NO (1) NO20075764L (enExample)
NZ (1) NZ562763A (enExample)
PL (1) PL1871380T3 (enExample)
PT (1) PT1871380E (enExample)
RU (1) RU2468800C2 (enExample)
WO (1) WO2006109881A1 (enExample)
ZA (1) ZA200709072B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
US7868045B2 (en) * 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
WO2009157397A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20160015100A (ko) 2014-07-30 2016-02-12 미래파인켐 주식회사 프로스타글란딘 중간체의 제조방법
KR20170025682A (ko) 2015-08-31 2017-03-08 미래파인켐 주식회사 프로스타글란딘 유도체의 신규한 제조방법
CN107582556A (zh) * 2017-09-15 2018-01-16 成都泠汐尚品科技有限公司 一种治疗消化性溃疡的药物复方制剂
CN108051553A (zh) * 2017-12-29 2018-05-18 武汉轻工大学 一种仔猪肠道功能保护剂的筛选方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
SE9804314D0 (sv) 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
ATE402925T2 (de) 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
JP4889219B2 (ja) 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
AU2004206141A1 (en) 2003-01-24 2004-08-05 Niva Shapira Synergistic compositions and methods for potentiating anti-oxidative activity
TWI367759B (en) 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid

Also Published As

Publication number Publication date
EP1871380B1 (en) 2011-10-19
WO2006109881A1 (en) 2006-10-19
EP1871380A1 (en) 2008-01-02
NO20075764L (no) 2008-01-14
KR20140069182A (ko) 2014-06-09
CA2602812C (en) 2014-11-18
RU2468800C2 (ru) 2012-12-10
US20070276006A1 (en) 2007-11-29
RU2007141655A (ru) 2009-05-20
AU2006234632B2 (en) 2011-10-27
ES2371658T3 (es) 2012-01-05
JP5711442B2 (ja) 2015-04-30
BRPI0610557A2 (pt) 2010-06-29
JP2013121972A (ja) 2013-06-20
IL186374A0 (en) 2008-03-20
DK1871380T3 (da) 2011-11-21
JP2008535774A (ja) 2008-09-04
KR101466980B1 (ko) 2014-12-01
ZA200709072B (en) 2008-11-26
PT1871380E (pt) 2011-11-21
PL1871380T3 (pl) 2012-03-30
CN101198334B (zh) 2013-02-06
KR20070119753A (ko) 2007-12-20
CN101198334A (zh) 2008-06-11
NZ562763A (en) 2010-12-24
US8962688B2 (en) 2015-02-24
AU2006234632A1 (en) 2006-10-19
CA2602812A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
ZA200709072B (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL212985A0 (en) Therapeutic uses of inhibitors of rtp801
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
ZA200708811B (en) Use of a sulfonamide compound for improving the pharma-cokinetics of a drug
IL193252A0 (en) N-hydroxyacrylamide compounds
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
IL181332A (en) A long-term treatment of human gastrointestinal disorders containing prostaglandin compound
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
IL177735A0 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
IL186286A0 (en) Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
HU0500145D0 (en) Composition for the treatment of oral diseases
EP1864671A4 (en) USE OF HYDROCHLORIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERTENSION
TWI365753B (en) Use of adamantyl methoxydiphenyl propenoic acid for the treatment of dermatological diseases
ZA200805701B (en) Salts of styphnic acid
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors
ZA200708279B (en) Dermatological compositions and salts for the treatment of dermatological diseases
ZA200606780B (en) Compounds for the treatment of diseases
HU0400847D0 (en) Pharmaceutical composition for the treatment of diabetes
SE0400574D0 (sv) A novel pharmaceutical composition for the treatment of psoriasis
AP2007003952A0 (en) Use of an anti-atherothrombotic compound inobtaining medicaments intended for the treatment of vascular disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees